1. Home
  2. CATY vs LUNG Comparison

CATY vs LUNG Comparison

Compare CATY & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cathay General Bancorp

CATY

Cathay General Bancorp

HOLD

Current Price

$49.81

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.54

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATY
LUNG
Founded
1962
1995
Country
United States
United States
Employees
1266
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CATY
LUNG
Price
$49.81
$2.54
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$50.80
$6.81
AVG Volume (30 Days)
400.1K
1.1M
Earning Date
01-21-2026
11-12-2025
Dividend Yield
2.73%
N/A
EPS Growth
9.40
N/A
EPS
4.33
N/A
Revenue
$711,617,000.00
$91,664,000.00
Revenue This Year
$18.83
$9.21
Revenue Next Year
$8.37
$5.03
P/E Ratio
$11.48
N/A
Revenue Growth
N/A
15.59
52 Week Low
$36.06
$1.31
52 Week High
$52.43
$9.37

Technical Indicators

Market Signals
Indicator
CATY
LUNG
Relative Strength Index (RSI) 57.77 71.32
Support Level $48.89 $1.96
Resistance Level $51.74 $1.74
Average True Range (ATR) 1.21 0.20
MACD 0.14 0.10
Stochastic Oscillator 59.10 91.13

Price Performance

Historical Comparison
CATY
LUNG

About CATY Cathay General Bancorp

Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: